CHAMPIONS ONCOLOGY

Company snapshot

Champions Oncology, Inc. provides an end-to-end range of research and development solutions and services that improve the productivity of oncology drug development. Using both in vitro to in vivo testing platforms companies can leverage the expertise at Champions Oncology to help guide decision making for clinical development scenarios. From screens using commercially-available and custom cell lin

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for CHAMPIONS ONCOLOGY. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for CHAMPIONS ONCOLOGY.

1. Jun 5, 2026 Clinical update

   Vitamin C — Unknown

2. Sep 29, 2009 Patent grant

   Synthesis of novel tubulin polymerization inhibitors: benzoylphenylurea (BPU) sulfur analogs

View all clinical trial activity →

• What is CHAMPIONS ONCOLOGY?

  Champions Oncology is a biotech organization headquartered in Hackensack, USA. It trades on NYSE under ticker CSBR. Primary therapeutic focus areas include Fontan Procedure. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 1 patent record(s) to this entity from

• Is CHAMPIONS ONCOLOGY publicly traded?

  Yes. CHAMPIONS ONCOLOGY is listed with ticker CSBR on NYSE per SEC EDGAR records linked on this profile.

• What drugs does CHAMPIONS ONCOLOGY develop or market?

  We link 2 drug profile(s) where CHAMPIONS ONCOLOGY is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/champions-oncology-inc#company-drugs.

• What are the latest developments for CHAMPIONS ONCOLOGY?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does CHAMPIONS ONCOLOGY focus on?

  CHAMPIONS ONCOLOGY focuses on Fontan Procedure based on our analysis of their pipeline programs and drug development activities.